home / stock / cara / cara quote
Last: | $0.2779 |
---|---|
Change Percent: | -3.99% |
Open: | $0.2735 |
Close: | $0.2779 |
High: | $0.2909 |
Low: | $0.2651 |
Volume: | 675,988 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.2779 | $0.2735 | $0.2779 | $0.2909 | $0.2651 | 675,988 | 07-02-2024 |
$0.263 | $0.272 | $0.263 | $0.284 | $0.261 | 971,251 | 07-01-2024 |
$0.258 | $0.285 | $0.258 | $0.31 | $0.258 | 6,217,701 | 06-28-2024 |
$0.3045 | $0.3001 | $0.3045 | $0.3198 | $0.2716 | 796,269 | 06-27-2024 |
$0.29 | $0.34 | $0.29 | $0.3689 | $0.29 | 868,467 | 06-26-2024 |
$0.3312 | $0.33 | $0.3312 | $0.34 | $0.3151 | 847,455 | 06-25-2024 |
$0.3399 | $0.2787 | $0.3399 | $0.349 | $0.2775 | 2,401,096 | 06-24-2024 |
$0.277 | $0.262 | $0.277 | $0.3288 | $0.2574 | 2,986,383 | 06-21-2024 |
$0.2466 | $0.26 | $0.2466 | $0.2697 | $0.24 | 738,171 | 06-20-2024 |
$0.2426 | $0.26 | $0.2426 | $0.2783 | $0.24 | 1,382,343 | 06-19-2024 |
$0.2426 | $0.26 | $0.2426 | $0.2783 | $0.24 | 1,382,343 | 06-18-2024 |
$0.2546 | $0.3567 | $0.2546 | $0.3601 | $0.24 | 4,242,192 | 06-17-2024 |
$0.35 | $0.45 | $0.35 | $0.4569 | $0.34 | 2,141,418 | 06-14-2024 |
$0.4436 | $0.4962 | $0.4436 | $0.5 | $0.42 | 3,228,833 | 06-13-2024 |
$0.6795 | $0.651 | $0.6795 | $0.7198 | $0.65 | 492,216 | 06-12-2024 |
$0.6629 | $0.6411 | $0.6629 | $0.67 | $0.6313 | 217,756 | 06-11-2024 |
$0.6728 | $0.6267 | $0.6728 | $0.6775 | $0.6267 | 251,977 | 06-10-2024 |
$0.6242 | $0.649 | $0.6242 | $0.6775 | $0.606 | 270,914 | 06-07-2024 |
$0.6421 | $0.6889 | $0.6421 | $0.6898 | $0.631 | 227,769 | 06-06-2024 |
$0.6951 | $0.6638 | $0.6951 | $0.705 | $0.6638 | 286,051 | 06-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
Cara Therapeutics Inc. Company Name:
CARA Stock Symbol:
NASDAQ Market:
Cara Therapeutics Inc. Website:
– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) – – Onset of action seen at Week 1 and sustained through Week 8 – – Statistical significance achieve...
KORSUVA™ (difelikefalin) injection U.S. commercial launch began in April 2022 and is tracking to expectation Kapruvia ® (difelikefalin) approved by European Commission for the treatment of moderate-to-severe pruritus associated with chronic kidney disease...
STAMFORD, Conn., May 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President an...